A forum for researchers, students and applicants in the field of cyclodextrin technology
The authors hypothesized that integrating tumor-targeted topoisomerase I inhibitor delivery with optimized PARP inhibitor scheduling could enable effective combination therapy
Compared with neostigmine, sugammadex promotes faster neuromuscular recovery, but its impact on diaphragmatic function and respiratory recovery in the morbidly
The success story of Cantrixil, a potent anti-cancer drug candidate, has been followed on our blog for years, and now
Oculis’s most advanced product candidate, OCS-01, is currently in Phase 3 development and aims to be the first eye drop
Rapid and complete reversal of residual neuromuscular blockade (rNMB) is essential for safe postoperative recovery in patients with myasthenia gravis
Rafael Holdings, Inc. announced that data from Cyclo Therapeutics’ Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick
Cyclodextrins (CDs) and their polymers are gaining momentum as advanced drug delivery systems. A recent review (https://www.sciencedirect.com/science/article/pii/S2590257125000203) highlights their progress
Cyclarity Therapeutics is pleased to announce regulatory approval to begin its first-in-human clinical trial. The trial will be conducted at CMAX,
New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer’s
Merck Sharp and Dohme LLC. has received initial U.S. Approval: 2017 PREVYMIS™ (letermovir) injection, for intravenous use. In the first
